Lung cancer is responsible for approximately 1 in 4 cancer deaths in the United States, making it the deadliest cancer among Americans. However, early detection and advancements in treatment can significantly improve patient outcomes.
PharmassêtX Inc., a late-preclinical stage pharmaceutical development company, today announced that the US Patent and Trademark Office has acknowledged receipt of the Company's patent application entitled "CRYSTALLINE FORM OF EPIGALLOCATECHIN-3-GALLATE." PharmassêtX is developing the novel form of epigallocatechin gallate (EGCG) as a prescription drug for the treatment of inflammatory bowel disease (IBD).
The AbbVie Foundation, a nonprofit working to advance health equity, is donating $75 million to UChicago Medicine to support the $815 million cost to construct a state-of-the-art cancer care pavilion, the first and only freestanding facility of its kind in Illinois.
The Danforth Technology Company (DTC) today announced the launch of Metablify, a startup that has developed a breakthrough technology platform that enables the detection and quantification of previously undetectable metabolites and chemicals in large numbers of biological samples processed using LC/MS data processing algorithms.
Fine-tuning the Tools that Enhance Reproducibility
Researchers at Rutgers University-New Brunswick, along with international collaborators, have introduced a novel method for identifying the crucial set of gut microbes commonly found in humans and essential for health.
Nipple-Sparing Mastectomy (NSM) is a surgical option for patients requiring a mastectomy, in which the breast tissue is removed while the skin, nipple, and areola remain intact. This procedure allows for immediate reconstruction and offers a more natural post-surgery result, giving patients both peace of mind and a sense of body confidence. M. Michele Blackwood, MD, FACS, director of Breast Surgery and director of Women’s Oncologic Health, RWJBarnabas Health and Rutgers Cancer Institute shares more on this surgical technique.
At 7-years-old, Amelia and Makenzie Kahn were diagnosed with juvenile Batten disease, an extremely rare and progressively fatal genetic disorder. Instead of giving in to the disease, the Kahn family searched for a treatment.
UC San Diego researchers discover two distinct molecular subtypes of Crohn’s disease using patient-derived organoids, opening the door to personalized treatment for the chronic inflammatory bowel disease.
Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common end-of-life condition for patients with advanced cancers, compared with haloperidol alone, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center.
CRI is co-hosting CICON24 to illuminate pioneering advances in cancer immunotherapy research starting September 8 in National Harbor, MD.
Advanced imaging and AI will power the manufacture of any cancer at the push of a button.
In an elegant fusion of science and medicine, neoantigen cancer vaccines are emerging as a formidable strategy in the battle against cancer. These vaccines, a testament to the power of personalized medicine, target cancer's unique protein signatures, rallying the immune system for a precise and potent attack.
A pivotal study uncovers the molecular signatures of mammographic calcifications in hormone receptor-positive, HER2-negative breast cancer.
In a notable advancement for Hodgkin's lymphoma (HL), recent research has introduced sophisticated therapeutic strategies designed to significantly boost patient outcomes.
Explore how scientists at St. Jude Children’s Research Hospital have identified causes for age-related differences in treatment outcomes of B-cell acute lymphoblastic leukemia.
At ADLM 2024 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo) in Chicago, more than 300 experts will present cutting-edge research and technology that will shape the future of laboratory medicine and improve patient care.
A new study identifies and validates a 10-gene biomarker that potentially predicts whether a stage II or III colon cancer patient will benefit from adjuvant chemotherapy. A secondary finding from the study suggests that the gene signature could potentially also predict whether immunotherapy would help some patients.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right